July 31, 2021 11:25 (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Kerala records 20,772 fresh COVID cases, state health minister says 'situation under control' | Both Indian men and women team register victories in Olympics hockey | Amid students' rush, Air India to increase flight frequency to US from August | Boxer Lovlina Borgohain ensured another medal for India from Tokyo Olympics. | OBC quota in medical colleges 'step taken late': BSP supremo Mayawati
UK gov't secures early access to 90mln doses of domestically-made COVID-19 vaccines

UK gov't secures early access to 90mln doses of domestically-made COVID-19 vaccines

India Blooms News Service | @indiablooms | 20 Jul 2020, 04:31 pm

Moscow/Sputnik: The UK government said on Monday it had entered partnerships with local developers of coronavirus vaccines and secured early access to over 90 million doses of three different types of vaccines and treatment for priority patients.

"Millions of people could be vaccinated against coronavirus as the UK secures early access to 90 million doses of promising Covid-19 vaccine candidates," the government said in a press release.

Announced by UK Business Secretary Alok Sharma, as quoted in the press release, the government entered partnerships with three domestic pharmaceutical developers for three different types of COVID-19 vaccines.

"As a result of these partnerships, England, Scotland, Wales and Northern Ireland could have access to enough doses to vaccinate and protect priority groups identified, such as frontline health and social care workers and those at increased health risk," the press release read.

Thirty million doses were secured with the BioNTech and Pfizer partnership developing an mRNA vaccine, which works by introducing sequences of molecules designed to make cells produce disease specific antigens and trigger a regular immune response.

Another 60 million doses of an inactivated whole virus vaccine, with the option to add a further 40 million doses, were secured through an in principle agreement with the Valneva pharmaceutical company.

For patients incapable of taking traditional vaccines, for example due to suffering cancer or autoimmune diseases, the government reached an in principle agreement with AstraZeneca for one million doses of a treatment containing coronavirus neutralizing antibodies.

As part of the same announcement, the UK government said it had opened an online registry where UK nationals can volunteer to participate in clinical trials of candidate vaccines. The hope is to get 500,000 people signed up by October.